Cas9 Stable Cell Line - LS 174T

The LS 174T cell line, derived from human colorectal adenocarcinoma, is an important model for gastrointestinal cancer research. These epithelioid cells possess unique characteristics, such as the production of carcinoembryonic antigen (CEA) and tumorigenicity in immunodeficient mice. The Cas9 stable cell line – LS 174T is a genetically engineered variant in which LS 174T cells stably express CRISPR-associated protein 9 (Cas9). This modification is achieved through lentiviral transduction or plasmid-based integration, ensuring stable Cas9 expression across cell generations.

The Cas9 stable cell line – LS 174T is crucial for high-throughput gene screening and functional genomics studies. Researchers utilize this cell line to investigate gene function in the pathogenesis of colorectal cancer, including oncogene activation, tumor suppressor gene inactivation, and drug resistance mechanisms. By introducing guide RNA (gRNA) targeting specific genes, scientists can perform gene knockout, gene knock-in, or transcriptional activation experiments to elucidate signaling pathways such as Wnt/β-catenin or EGFR. This cell line can also accelerate drug development, rapidly validating therapeutic targets and evaluating anticancer compounds in a genetically defined context. Furthermore, it can facilitate the construction of personalized cancer models by introducing patient-derived mutations, thereby contributing to the advancement of precision oncology.